GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (FRA:NVV1) » Definitions » Cyclically Adjusted PB Ratio

Novavax (FRA:NVV1) Cyclically Adjusted PB Ratio : 9.27 (As of Jul. 19, 2025)


View and export this data going back to . Start your Free Trial

What is Novavax Cyclically Adjusted PB Ratio?

As of today (2025-07-19), Novavax's current share price is €5.93. Novavax's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €0.64. Novavax's Cyclically Adjusted PB Ratio for today is 9.27.

The historical rank and industry rank for Novavax's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:NVV1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.39   Med: 3.21   Max: 35.13
Current: 10.26

During the past years, Novavax's highest Cyclically Adjusted PB Ratio was 35.13. The lowest was 0.39. And the median was 3.21.

FRA:NVV1's Cyclically Adjusted PB Ratio is ranked worse than
88.79% of 678 companies
in the Biotechnology industry
Industry Median: 1.66 vs FRA:NVV1: 10.26

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novavax's adjusted book value per share data for the three months ended in Mar. 2025 was €-0.432. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.64 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novavax Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Novavax's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Cyclically Adjusted PB Ratio Chart

Novavax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.49 17.17 1.43 1.02 4.78

Novavax Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 3.93 5.21 4.78 9.39

Competitive Comparison of Novavax's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PB Ratio falls into.


;
;

Novavax Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novavax's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=5.93/0.64
=9.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Novavax's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.432/134.9266*134.9266
=-0.432

Current CPI (Mar. 2025) = 134.9266.

Novavax Quarterly Data

Book Value per Share CPI Adj_Book
201506 25.711 100.684 34.455
201509 24.239 100.392 32.577
201512 19.903 99.792 26.910
201603 12.299 100.470 16.517
201606 7.236 101.688 9.601
201609 3.271 101.861 4.333
201612 -0.388 101.863 -0.514
201703 -1.925 102.862 -2.525
201706 -3.626 103.349 -4.734
201709 -4.011 104.136 -5.197
201712 -5.319 104.011 -6.900
201803 -4.648 105.290 -5.956
201806 -3.934 106.317 -4.993
201809 -5.673 106.507 -7.187
201812 -7.679 105.998 -9.775
201903 -5.677 107.251 -7.142
201906 -6.994 108.070 -8.732
201909 -6.752 108.329 -8.410
201912 -5.175 108.420 -6.440
202003 -0.403 108.902 -0.499
202006 2.677 108.767 3.321
202009 1.436 109.815 1.764
202012 7.266 109.897 8.921
202103 11.786 111.754 14.230
202106 8.334 114.631 9.810
202109 5.200 115.734 6.062
202112 -4.104 117.630 -4.707
202203 0.759 121.301 0.844
202206 -5.046 125.017 -5.446
202209 -7.284 125.227 -7.848
202212 -6.957 125.222 -7.496
202303 -9.694 127.348 -10.271
202306 -7.385 128.729 -7.741
202309 -5.353 129.860 -5.562
202312 -4.712 129.419 -4.913
202403 -5.683 131.776 -5.819
202406 -2.508 132.554 -2.553
202409 -2.962 133.029 -3.004
202412 -3.714 133.157 -3.763
202503 -0.432 134.927 -0.432

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novavax  (FRA:NVV1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novavax Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Novavax's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax Business Description

Industry
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Novavax Headlines

No Headlines